Table 3.

AD animal research quality evaluation form.

Study	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	Quality Score	Quality Score (%)
Ji-Jing Yan 2001	√	×	√	×	×	×	√	√	√	√	6	60
Hee-Sung KIM 2004	√	×	×	×	×	×	√	√	√	√	5	50
Jae-Young Cho 2005	√	×	×	×	×	×	√	√	√	√	5	50
Takayoshi Mamiya 2008	√	×	√	×	×	×	√	√	√	√	6	60
Tsuyoshi Hamaguchi 2009	√	√	×	×	×	×	√	√	√	√	6	60
JIN Beibei 2011	√	×	√	×	×	×	√	√	√	√	6	60
Ji-Jing Yan 2013	√	×	√	×	×	×	√	√	√	√	6	60
Takashi Mori 2013	√	×	×	×	×	×	√	√	√	√	5	50
Fan-Shiu Tsai 2015	√	√	√	√	×	×	√	√	√	√	8	80
Haung Hao 2016	√	√	√	×	×	×	√	√	√	√	7	70
Masaki Kikugawa 2016	√	×	×	×	×	×	√	√	√	√	5	50
Takashi Mori 2017	√	×	×	×	×	×	√	√	√	√	5	50
Wang Yue 2017	√	√	√	×	×	×	√	√	√	√	7	70
MING Rui 2018	√	×	√	×	×	×	√	√	√	√	6	60
Mohd Faraz Zafeer 2019	√	×	×	×	×	×	√	√	√	√	5	50
Takashi Mori 2019	√	√	×	√	×	×	√	√	√	√	7	70
WANG Qian 2019	√	√	√	×	×	×	√	√	√	√	7	70

√ = fulfilling the criterion, × = not fulfilling the criterion. (1) peer-reviewed publication; (2) presence of randomization of subjects into treatment groups; (3) assessment of dose–response relationship; (4) blinded assessment of behavioral outcome; (5) monitoring of physiological parameters such as body temperature; (6) calculation of necessary sample size to achieve sufficient power; (7) statement of compliance with animal welfare regulations; (8) avoidance of anesthetic agents with marked intrinsic neuroprotective properties (e.g., ketamine); (9) statement of potential conflict of interests; (10) use of a suitable animal model.